Supplementary Table 1 – SNP Tagging details

Total SNPs MAF > 0.05 discovered	SNPs MAF > 0.05 in Caucasians	Tag SNPs selected for Rp^2 > 0.8	Usable Tag SNPs	Common Caucasian SNPs tagged with Rp^2 > 0.8
396	227	68	60	219 (96%)

Supplementary Table 2 Genotype Distributions of 60 Tag SNPs in Stage 1 (SEARCH Set 1). Values in the MAF column refer only to Controls. SNPs with results shown in **bold** progressed to Stage 2

* Referent group

Block	rs Number	MAF	Genotype	Controls	Cases	Odds Ratio (95% CI)	Trend Test P-Value
1	rs2077647	0.47	AA	612	602	1*	0.50
			AG	1177	1070	0.92 [0.80-1.06]	
			GG	484	510	1.07 [0.91-1.27]	
1	rs746432	0.1	CC	1847	1807	1*	0.31
			CG	396	342	0.88 [0.75-1.03]	
			GG	17	22	1.32 [0.70-2.50]	
1	rs532010	0.38	TT	850	798	1*	0.20
			TC	1089	1027	1.00 [0.88-1.14]	
			CC	309	335	1.15 [0.96-1.39]	
1	rs7766762	0.13	AA	1721	1671	1*	0.37
			AG	513	448	0.90 [0.78-1.04]	
			GG	30	35	1.20 [0.73-1.97]	
1	rs3778610	0.01	AA	2217	2134	1*	0.73
			AG	61	53	0.90 [0.62-1.31]	
			GG	0	1	103.9 [0.0-37.3]	
2	rs3853251	0.33	TT	1020	921	1*	0.09
			TC	988	993	1.11 [0.98-1.26]	
			CC	258	263	1.13 [0.93-1.37]	
2	rs2234693 PvuII	0.46	TT	669	628	1*	**0.36**
			TC	1128	1073	1.01 [0.88-1.16]	
			CC	471	480	1.09 [0.92-1.28]	
2	rs9340799 Xba1	0.35	AA	933	799	1*	**0.06**
			AG	972	931	1.12 [0.98-1.27]	
			GG	265	263	1.16 [0.95-1.41]	
3	rs1709182	0.36	TT	915	820	1*	**0.09**
			TC	1019	1024	1.12 [0.99-1.27]	
			CC	308	313	1.13 [0.94-1.36]	
3	rs1514348	0.39	AA	830	748	1*	0.04
			AC	1096	1064	1.08 [0.95-1.23]	
			CC	343	372	1.20 [1.01-1.44]	
3	rs2431260	0.27	CC	1187	1111	1*	0.45
			CG	863	821	1.02 [0.90-1.15]	
			GG	175	139	0.85 [0.67-1.08]	
3	rs1033181	0.07	AA	1981	1910	1*	0.29
			AG	284	258	0.94 [0.79-1.13]	
			GG	12	6	0.52 [0.19-1.38]	
3	rs2175898	0.48	AA	616	592	1*	0.65
			AG	1119	1099	1.02 [0.89-1.18]	
			GG	542	500	0.96 [0.81-1.13]	
3	rs9478249	0.40	GG	806	816	1*	0.07
			GT	1106	1029	0.92 [0.81-1.05]	
			TT	363	315	0.86 [0.72-1.03]	

Block	rs Number	MAF	Genotype	Controls	Cases	Odds Ratio (95% CI)	Trend Test P-Value
			GG	1018	950	1*	
3	rs9340835	0.33	GA	1002	989	1.06 [0.93-1.20]	0.35
			AA	252	252	1.07 [0.88-1.30]	
			CC	1301	1204	1*	
3	rs9322335	0.25	CT	826	859	1.12 [0.99-1.27]	0.57
			TT	152	124	0.88 [0.69-1.13]	
			CC	1868	1803	1*	
3	rs9371559	0.09	CG	370	354	0.99 [0.85-1.16]	0.42
			GG	23	12	0.54 [0.27-1.09]	
			CC	2121	2032	1*	
3	rs9322337	0.04	CA	152	155	1.06 [0.84-1.34]	0.76
			AA	4	2	0.52 [0.10-2.85]	
			TT	898	849	1*	
3	rs6557168	0.37	TC	1037	1011	1.03 [0.91-1.17]	0.99
			CC	315	291	0.98 [0.81-1.18]	
			CC	1308	1269	1*	
4a	rs9322340	0.24	CT	848	780	0.95 [0.84-1.07]	0.79
			TT	199	137	1.19 [0.92-1.54]	
			TT	2012	1938	1*	
4a	rs9340851	0.06	TC	261	236	0.94 [0.78-1.13]	0.87
			CC	6	11	1.90 [0.70-5.16]	
			GG	2069	2001	1*	
4a	rs4365941	0.05	GA	198	182	0.95 [0.77-1.17]	0.47
			AA	7	4	0.59 [0.17-2.02]	
			GG	1878	1821	1*	
4a	rs1606678	0.09	GA	376	337	0.92 [0.79-1.09]	0.63
			AA	16	21	1.35 [0.70-2.60]	
			AA	937	893	1*	
4a	rs2347923	0.35	AC	1048	1000	1.00 [0.88-1.14]	0.52
			CC	270	279	1.08 [0.90-1.31]	
			AA	1662	1559	1*	
4a	rs988328	0.15	AG	565	576	1.09 [0.95-1.24]	0.32
			GG	52	49	1.00 [0.68-1.49]	
			GG	1040	1005	1*	
4a	rs4583998	0.32	GA	1026	957	0.97 [0.85-1.09]	0.66
			AA	207	223	1.11 [0.91-1.37]	
			CC	1367	1301	1*	
4a	rs1801132	0.22	CG	805	777	1.01 [0.90-1.15]	0.40
			GG	102	114	1.17 [0.89-1.55]	
			TT	1078	937	1*	
4b	rs3020314	0.31	TC	984	1007	1.18 [1.04-1.33]	**0.003**
			CC	213	236	1.27 [1.04-1.56]	
			TT	1494	1389	1*	
4b	rs3020317	0.19	TC	707	705	1.07 [0.94-1.22]	**0.10**
			CC	76	90	1.27 [0.93-1.74]	
			AA	1749	1640	1*	
4b	rs985191	0.12	AC	509	529	1.11 [0.96-1.27]	0.13
			CC	19	21	1.18 [0.63-2.20]	
			AA	1421	1370	1*	
4b	rs3003925	0.21	AG	779	717	0.95 [0.84-1.08]	0.60
			GG	79	101	1.33 [0.98-1.80]	

Block	rs Number	MAF	Genotype	Controls	Cases	Odds Ratio (95% CI)	Trend Test P-Value
			AA	1515	1417	1*	
4c	rs6557178	0.18	AG	687	693	1.08 [0.95-1.23]	0.25
			GG	68	69	1.08 [0.77-1.53]	
			AA	1587	1485	1*	
4c	rs7382115	0.17	AG	611	618	1.08 [0.95-1.23]	0.23
			GG	71	73	1.10 [0.79-1.53]	
			AA	943	842	1*	
4c	rs1884054	0.35	AC	1058	1056	1.12 [0.99-1.27]	0.03
			CC	270	288	1.19 [0.99-1.44]	
			AA	1143	1109	1*	
4c	rs3020404	0.30	AG	921	896	1.00 [0.89-1.13]	0.44
			GG	211	181	0.88 [0.71-1.10]	
			AA	1105	981	1*	
4c	rs3020405	0.30	AG	971	976	1.13 [1.00-1.28]	0.008
			GG	183	208	1.28 [1.03-1.59]	
			CC	1878	1749	1*	
4c	rs726282	0.09	CA	385	423	1.18 [1.01-1.37]	0.02
			AA	15	20	1.43 [0.73-2.81]	
			CC	1311	1187	1*	
4c	rs926777	0.24	CA	854	868	1.12 [0.99-1.27]	**0.008**
			AA	110	135	1.36 [1.04-1.76]	
			AA	1112	979	1*	
4c	rs3020407	0.30	AG	962	987	1.17 [1.03-1.32]	0.006
			GG	199	218	1.24 [1.01-1.54]	
			CC	1698	1588	1*	
4c	rs2144025	0.13	CT	542	548	1.08 [0.94-1.24]	0.11
			TT	36	46	1.37 [0.88-2.12]	
			TT	1301	1209	1*	
4d	rs6916218	0.24	TA	817	825	1.09 [0.96-1.23]	0.34
			AA	140	133	1.02 [0.80-1.31]	
			TT	1809	1727	1*	
4d	rs7754762	0.11	TA	447	437	1.02 [0.88-1.19]	0.56
			AA	20	24	1.26 [0.69-2.28]	
			CC	1510	1400	1*	
4d	rs3020416	0.04	CG	649	693	1.15 [1.01-1.31]	0.37
			GG	98	76	0.84 [0.61-1.14]	
			GG	1224	1107	1*	
4d	rs926779	0.27	GA	879	919	1.16 [1.02-1.31]	0.14
			AA	173	159	1.02 [0.81-1.28]	
			AA	1915	1810	1*	
4d	rs2273207	0.08	AG	342	353	1.09 [0.93-1.28]	0.14
			GG	9	15	1.76 [0.77-4.04]	
			TT	1631	1521	1*	
4d	rs3020372	0.16	TC	569	608	1.15 [1.00-1.31]	0.39
			CC	71	52	0.79 [0.55-1.13]	
			AA	1365	1271	1*	
4d	rs3020376[1]	0.25	AG	646	660	1.10 [0.96-1.25]	0.35
			GG	230	222	1.04 [0.85-1.27]	
			CC	1404	1303	1*	
4d	rs2982896	0.21	CT	746	754	1.09 [0.96-1.24]	0.33
			TT	109	102	1.01 [0.76-1.33]	

Block	rs Number	MAF	Genotype	Controls	Cases	Odds Ratio (95% CI)	Trend Test P-Value
			GG	1053	968	1*	
4d	rs2459107	0.32	GA	981	982	1.09 [0.96-1.23]	0.25
			AA	243	239	1.07 [0.88-1.31]	
			AA	1969	1868	1*	
5	rs9341052	0.07	AG	293	309	1.11 [0.94-1.32]	0.39
			GG	15	11	0.77 [0.35-1.69]	
			TT	1854	1738	1*	
5	rs3778099	0.10	TC	405	424	1.12 [0.96-1.30]	0.11
			CC	18	22	1.30 [0.70-2.44]	
			CC	1816	1752	1*	
5	rs2747647	0.11	CG	433	415	0.99 [0.86-1.15]	0.83
			GG	24	21	0.91 [0.50-1.64]	
			CC	1268	1162	1*	
5	rs3020384	0.26	CG	834	891	1.17 [1.03-1.32]	0.54
			GG	176	137	0.85 [0.67-1.08]	
			GG	1980	1925	1*	
5	rs9341066	0.07	GA	289	253	0.90 [0.75-1.08]	0.37
			AA	6	8	1.37 [0.47-3.96]	
			GG	1490	1420	1*	
5	rs2228480	0.19	GA	695	671	1.01 [0.89-1.15]	0.56
			AA	91	97	1.12 [0.83-1.50]	
			AA	638	616	1*	
5	rs3798577	0.46	AG	1155	1088	0.98 [0.85-1.12]	0.75
			GG	478	477	1.03 [0.87-1.22]	
			TT	1970	1877	1*	
5	rs1062577	0.07	TA	284	294	1.09 [0.91-1.29]	0.61
			AA	13	8	0.65 [0.27-1.56]	
			AA	1370	1371	1*	
5	rs2813544	0.22	AG	801	711	0.89 [0.78-1.01]	0.19
			GG	100	101	1.01 [0.76-1.34]	
			GG	667	639	1*	
5	rs1543404	0.46	GA	1111	1067	1.00 [0.87-1.15]	0.98
			AA	497	475	1.00 [0.84-1.18]	
			CC	616	592	1*	
5	rs2747652	0.48	CT	1100	1066	1.01 [0.88-1.16]	0.69
			TT	531	492	0.96 [0.82-1.14]	
			TT	1311	1247	1*	
5	rs2813549	0.24	TC	834	796	1.00 [0.89-1.14]	0.51
			CC	127	137	1.13 [0.88-1.46]	

All genotype distributions in controls conform to Hardy-Weinberg equilibrium with $p>0.01$ with the exception of [1] where no obvious reason for the deviation could be ascertained.

Supplementary Table 3 Results for SNPs, tagged by rs3020314, in SEARCH Set 1.

rs Number	MAF	Rp2 with rs3020314	Genotype	Controls	Cases	Odds Ratio (95% CI)	Trend Test P-Value
			TT	1078	937	1*	
rs3020314	0.31	*	TC	984	1007	1.18 [1.04-1.33]	**0.003**
			CC	213	236	1.27 [1.04-1.56]	
			AA	1078	945	1*	
rs3020377	0.31	0.99	AG	982	1001	1.16 [1.03-1.32]	**0.004**
			GG	213	237	1.27 [1.03-1.56]	
			CC	1083	951	1*	
rs3020390	0.31	0.98	CT	988	1005	1.06 [1.02-1.31]	**0.005**
			TT	207	231	1.27 [1.03-1.56]	
			TT	1083	941	1*	
rs3020394	0.31	0.96	TC	968	1002	1.19 [1.05-1.35]	**0.003**
			CC	211	229	1.25 [1.02-1.54]	
			AA	1108	970	1*	
rs3020396	0.30	0.92	AG	956	987	1.18 [1.04-1.33]	**0.004**
			GG	201	221	1.26 [1.02-1.55]	
			AA	1101	966	1*	
rs3020400	0.30	0.92	AG	958	981	1.17 [1.03-1.32]	**0.005**
			GG	196	217	1.26 [1.02-1.56]	
			TT	1110	974	1*	
rs3020401	0.30	0.92	TC	964	994	1.18 [1.04-1.33]	**0.004**
			CC	200	221	1.26 [1.02-1.55]	
			AA	1072	960	1*	
rs1884051	0.31	0.88	AG	998	1004	1.12 [0.99-1.27]	**0.030**
			GG	208	223	1.20 [0.97-1.47]	

- Referent group

Supplementary Table 4: Characteristics of the 28 studies within the Breast Cancer Association Consortium (BCAC)

Study name (Reference)	Case definition and ascertainment	Control definition and ascertainment	Proportion participating	No. of (cases) (controls)	Age range (cases) (controls)
ABCFS **1** Australian Breast Cancer Family Study	All cases diagnosed < age 40 plus a random sample of those diagnosed ages 40-59 from cancer registries in Victoria & New South Wales, plus a limited number diagnosed aged 60-69; cases living in Melbourne recruited from 1992-99 & in Sydney from 1993-98.	Identified from the electoral rolls in Melbourne from 1992-98 & Sydney from 1993-99. Frequency matched to cases by age in 5 year categories.	75% of cases & 68% of controls completed questionnaires, 71% of cases & 55% of controls provided a blood sample [30].	1096 606	20-68 18-69
ABCS **2** Amsterdam Breast Cancer Study	All cases aged <50 & diagnosed from 1974-1994 in 4 Dutch hospitals. Familial non-BRCA1/2 cases <50 from Clinical Genetic Centre in the Netherlands Cancer Institute	Random women <50 years of age at baseline From 2 population-based prospective studies by National Institute for Public Health & the Environment, The Netherlands.	85% of cases & ~50% of controls	1320 551	23-50 20-50
BBCC **3** Bavarian Breast Cancer Cases and Controls	Consecutive, unselected cases with invasive breast cancer at the University Breast Centre, Franconia in Northern Bavaria.	Healthy women with no diagnosis of cancer aged 55 or older. Invited by a newspaper advertisement.	95% of cases & 99% of controls provided a blood sample & an epidemiological questionnaire.	1009 816	22-95 >55
BBCS **4** 1) British Breast Cancer Study 2) Mammography Oestrogens and Growth Factors Study	1) English & Scottish Cancer Registries All breast cancer cases who developed a first primary before age 65 in 1971 or later & who subsequently developed a second primary cancer. Unilateral breast cancer cases diagnosed before age 70 in 1971 or later.	1) A friend, sister-in-law or daughter-in-law of cases 2) Selected from a cohort of healthy women participating in a mammographic screening trial near the time of their final mammogram, frequency matched to cases on geographical area of residence	1) 68% of cases & 76% of controls provided a blood sample. 2) 82% provided a blood sample.	676 732	25-70 24-81
CGPS **5** Copenhagen Breast Cancer Study and Copenhagen City Heart Study	Consecutive, incident cases from a hospital with centralized care for a population of 320,000 women from 2001 to the present.	Community controls with no history of breast cancer from the Copenhagen General Population Study. All controls were known to be breast cancer-free at the end of 2004.	96% of cases & 56% of controls were interviewed & provided a blood sample.	1948 2974	29-93 20-90
CNIO-BCS **6** Spanish National Cancer Centre Study	Two groups of cases: 1) 574 consecutive breast cancer patients, unselected for family history, from 3 public hospitals, 2 in Madrid & one in Oviedo, from 2000 to 2005. 2) 290 cases with at	Women attending the Menopause Research Centre between 2000 & 2004 & female members of the College of Lawyers attending a free, targeted medical	Not recorded.	736 817	22-86 23-86

Study name (Reference)	Case definition and ascertainment	Control definition and ascertainment	Proportion participating	No. of (cases) (controls)	Age range (cases) (controls)
	least one first degree relative also affected with breast cancer, recruited through the CNIO family cancer clinic in Madrid from 2000 to 2004.	check-up in 2005, all free of breast cancer			
GENICA 7 Gene Environment Interaction and Breast Cancer in Germany	Incident cases enrolled between 2000 & 2004 from the Greater Bonn area; all enrolled within 6 months of diagnosis	Selected from population registries from 31 communities; matched to cases in 5-year age classes	Response rate 88% for cases & 67% for controls. DNA for 89% & 88% respectively.	945 984	23-80 24-80
GC-HBOC 8 German familial breast cancer study	Index patients from German breast cancer families non-*BRCA1* /2, collected 1996-2007 via Institute of Human Genetics, Heidelberg & Department of Gynaecology & Obstetrics, Cologne, Germany.	Healthy, unrelated, ethnically matched female blood donors recruited in 2004 & 2007 by German Red Cross Blood Service of Baden-Württemberg-Hessen, Institute of Transfusion Medicine & Immunology, Mannheim.		525 920	20-87 19-68
HABCS 9 Hannover Breast Cancer Study	Cases who received radiotherapy for breast cancer at Hannover Medical School between 1997-2003, unselected for age or family history	Anonymous female blood bank donors at Hannover Medical School, collected from 8/2005-12/2005, with known age & ethnic background	Approx. 80% of cases & 70% of controls contacted gave a blood sample	1044 1014	25-91 18-68
HEBCS 10 Helsinki Breast Cancer Study	Consecutive, incident cases (884) from Department of Oncology, Helsinki University Central Hospital 1997-8 & 2000	Healthy females recruited from the same geographical region in Southern Finland	79% of all cases for the consecutive series	1455 1090	21-96 18-65
KARBAC 11 Karolinska Breast Cancer study	1. Familial cases from Department of Clinical Genetics, Karolinska University Hospital , Stockholm 2. Consecutive cases from Department of Oncology, Huddinge & Söder Hospital, Stockholm 1998-2000	Blood donors of mixed gender from same geographical region	1. NA 2. 70% of consecutive cases provided a blood-sample	819 863	24-92 Unknown
KBCP 12 Kuopio Breast Cancer Project	Women at Kuopio University Hospital between 1990 & 1995 who were found to have breast cancer	Age & long-term area-of-residence matched controls selected from the National Population Register & interviewed in parallel with the cases	Cases: 98% of those contacted; 86% of those potentially eligible. Controls selected individually for each case	455 397	44-91 37-77
kConFab/AOCS 13 Kathleen Cuningham	Cases were from multiple-case breast & breast-ovarian families recruited though family	Female controls were ascertained by the Australian Ovarian Cancer	65% of female family members gave DNA 64% filled in	264 820	25-78 Unknown

Study name (Reference)	Case definition and ascertainment	Control definition and ascertainment	Proportion participating	No. of (cases) (controls)	Age range (cases) (controls)
Foundation Consortium for Research into Familial Breast Cancer (kConFaB)	cancer clinics from 1998 to the present. Non-*BRCA1* /2. Case was youngest breast cancer affected family member.	Study identified from the electoral rolls.	questionaires		
MARIE **14** Mammary carcinoma risk factor investigation	Incident and prevalent cases diagnosed from 2001-2005 in the study region Hamburg in Northern Germany, and from 2002-2005 in the study region Rhein-Neckar-Karlsruhe in Southern Germany.	2 controls per case were randomly drawn from population registries and frequency matched by birth year to the case.	64.1% of cases & 43.4% of controls participated	1612 3203	50-75
MCBCS **15** Mayo Clinic Breast Cancer Study	Incident cases residing in 6 states (MN, WI, IA, IL, ND, SD) seen at the Mayo Clinic in Rochester, MN from 2002-5	Women without cancer presenting for general medical examination at the Mayo Clinic. Controls were recruited concurrently with cases & were frequency matched to cases on age, ethnicity & county/state.	68% cases, 77% controls were interviewed & provided a blood sample.	779 823	24-87 20-90
MCCS **16**	Incident cases diagnosed within the Melbourne Collaborative cohort study during the follow-up from baseline (1990-1994) to 2004 of the 24469 participating women	Random sample of the initial cohort	All incident cases and all the controls in the random sample. DNA available from >95% of the participants.	476 576	37-80 37-70
MEC **17** Multiethnic Cohort	Incident cases identified from SEER cancer registries in Los Angeles County & State registries in California & Hawaii, USA from 1993-2002. Grouped by self-reported ethnicity.	Women without cancer from the same States, recruited concurrently with cases & frequency matched to cases by age at blood-draw & self-reported ethnicity.	>60% for both cases & controls	Japanese: 414 361 Whites: 391 403	65.0 (mean) 65.9 (mean) 65.3 (mean) 64-0 (mean)
NBCS **18** Norwegian Breast Cancer Study	Incidence cases from three different hospitals: 1) Cases (114) mean age 64 (28-92) at Ullevål Univ. Hospital 1990-94, 2) cases (182) mean age 59 (26-75) referred to Norwegian Radium Hospital 1975-1986, 3) cases (124), mean age 56 (29-82)) with stage I or II disease, in the Oslo micro-metastases study at Norwegian Radium Hospital between 1995-1998, 4) cases (71) mean age 67 (37–82) with locally advanced disease at Haukeland Univ.	Control subjects were healthy women, age 55-71, residing in Tromsø (440), and Bergen (109) attending the Norwegian Breast Cancer Screening Program.	80-82% cases and 70% controls	590 1096	62.5 (26-92)

Study name (Reference)	Case definition and ascertainment	Control definition and ascertainment	Proportion participating	No. of (cases) (controls)	Age range (cases) (controls)
	Hospital.				
NHS **19** USA Nurses Health Study	Incident cases arising in the sub-cohort of 32,826 cohort members who gave a blood specimen in 1989-1990 are included if they were diagnosed with breast cancer prior to July 1, 2000.	Controls were women in this sub-cohort who were not diagnosed with breast cancer,	All incident cases and selected controls are included.	955 1631	
ORIGO **20** Leiden University Medical Centre Breast Cancer Study	Consecutive cases diagnosed 1996-2006 in 2 hospitals of South-West Netherlands (Leiden & Rotterdam). No selection for family history; Rotterdam cases selected for diagnosis aged <70. Cases with in situ carcinomas eligible.	Blood bank healthy donors from same geographical locale.	80-90%	443 419	21-87 Unknown
PBCS **21** Polish Breast Cancer Study	Incident cases from 2000-3, identified through a rapid identification system in participating hospitals covering ~ 90% of all eligible cases; periodic check against the cancer registries in Warsaw & Łódź to assure complete identification of cases	Randomly selected from population lists of all residents of Poland, stratified & frequency matched to cases by case city & age in 5 year categories.	79% of eligible cases & 69% of eligible controls agreed to interview; 84% of interviewed cases & 94% of interviewed controls provided a DNA sample	1957 2341	20-74 20-74
SASBAC **22** Singapore and Swedish Breast Cancer Study	Incident cases from October 1993 to March 1995 identified via the 6 regional cancer registries in Sweden, to which reporting is mandatory.	Controls were randomly selected from the total population registry in 5-year age groups to match the expected age-frequency distribution among cases.	84% of cases & 82% of controls questionnaire, 87% & 74% of those donated DNA (overall 73% & 61% respectively).	1292 1498	50-74 50-74
SEARCH Sets 1/2 **23** Studies of Epidemiology and Risk Factors in Cancer Heredity	Cases identified through East Anglian Cancer Registry; 1) prevalent cases diagnosed age <55 from 1991-6 & alive when study started in 1996; 2) incident cases diagnosed age < 70 from 1996 -2004.	Selected from the EPIC-Norfolk cohort study of 25,000 individuals age 45-74, based in the same geographic region as cases	64% of eligible cases & 41% of invited controls provided a blood sample	4346 4541	25-69 42-80
SEARCH Set 3 **24**	Ongoing Collection (as above) of incident cases diagnosed age < 70 from 2004 to 2007.	Selected from the EPIC-Norfolk cohort study of 25,000 individuals age 45-74, based in the same geographic region as cases	64% of eligible cases & 41% of invited controls provided a blood sample	2301 2273	25-69 42-80
SEBCS **25** Seoul Breast Cancer Study	Consecutive, incident, cases from 2 hospitals in Seoul recruited 2001-2005	Healthy community controls from same catchment area & participating in annual health	~ 85% of cases, 75% of controls interviewed & provided a blood sample.	1724 1160	≥40 ≥ 40

Study name (Reference)	Case definition and ascertainment	Control definition and ascertainment	Proportion participating	No. of (cases) (controls)	Age range (cases) (controls)
		check-up, 2001-2005.			
TWBCS **26** Taiwanese Breast Cancer study	Incident cases diagnosed & treated at 2 major teaching hospitals in Taiwan;	Controls cancer-free individuals, randomly selected from women attending health exam. at same hospital during study period. Underwent 1-day health examination - any showing evidence cancer excluded.	>90% cases & ~ 40% of controls	863 852	30-70 30-70
UCIBCS **27** UCI Breast Cancer Study	All cases diagnosed in Orange County, California, during one-year period beginning March 1, 1994. Ascertained through the population-based Cancer Surveillance Program of Orange County California (CSPOC)	Female control under age 75 years without history of cancer recruited using random digit dialing among Orange County residents & frequency matched to cases by age & race/ethnicity.		1081 596	
USRTS **28** U.S. Radiologic Technologist Study	Prevalent cases identified through mailed surveys in 1983-8 & 1994-8, incident cases between surveys; blood collected from 1999-2004; unselected for family cancer history or any other characteristics; most cases sampled more than 5 years after diagnosis	Selected from women within the cohort without breast cancer as of 1999, blood collected between 2000-2004; matched to cases on year of birth in 5-year strata	62% of cases & 48% of controls contacted agreed to provide a blood sample & were interviewed	704 1033	19-84 t dx 41-99 at interview 41-91 at interview

1 Dite, G.S. et al. Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations. *J. Natl. Cancer Inst.,* **95**, 448-57 (2003).

2 M. K. Schmidt, et al. Breast Cancer Survival and Tumor Characteristics in Premenopausal Women Carrying the CHEK2*1100delC Germline Mutation, *J.C.O.*, **06**, 3024 (2006)

M.K. Schmidt, et al. (2007). Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the Breast Cancer Association Consortium. *Cancer Res.*, **67,** 9584-90 (2007)

3 Fasching PA, et al. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. *Breast Cancer Res Treat.* DOI 10.1007/s10549-007-9822-2 (2007)

Schrauder M, et al. Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer. *J. Cancer Res. Clin. Oncol.,***134**, 873-82 (2008).

4 Johnson, N. et al. Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study. *Lancet,* **366**, 1554-7 (2005).

Fletcher, O. et al. Inconsistent association between the STK15 F31I genetic polymorphism and breast cancer risk. *J. Natl. Cancer. Inst.,* **98**, 1014-8 (2006).

5 Bojesen, S.E et al. No association of breast cancer risk with integrin beta3 (ITGB3) Leu33Pro genotype. *Br. J. Cancer*, **93**, 167-171 (2005).

Weischer, M. et al. Increased Risk of Breast Cancer Associated With CHEK2*1100delC. *J. Clin. Oncol*., (2006).

6 Ribas, G. et al. Evaluating HapMap SNP data transferability in a large-scale genotyping project involving 175 cancer-associated genes. *Hum. Genet.,* **118**, 669-79 (2006).

Milne, RL et al. ERCC4 associated with breast cancer risk: a two stage case-control study using high throughput genotyping. *Cancer Res.*, **66,** 9420-7 (2006)

7 Pesch, B. et al. Factors modifying the association between hormone –replacement therapy and breast cancver risk. Eur. J. Epidemiol., 20:699-711 (2005)

8 Wirtenberger,M., et al. Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer. *Carcinogenesis*, **27**, 2201-2208 (2006)

Frank, B. et al. Association of the CASP10 V410I variant with reduced familial breast cancer risk and interaction with the CASP8 D302H variant. *Carcinogenesis*, **27**, 606-9 (2006)

9 Dork, T. et al. Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. *Cancer Res.,* **61**, 7608-7615 (2001).

10 Syrjakoski, K. et al. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. *J. Natl. Cancer Inst.,* **92**, 1529-31 (2000).

Kilpivaara, O. et al. Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. *Int J. Cancer,* **113**, 575-80 (2005).

11 Lindblom, A. et al. Hereditary breast cancer in Sweden: a predominance of maternally inherited cases. *Breast Cancer Res. Treat.,* **24,** 159-65 (1992)

Margolin S. et al. BRCA1 mutations in a population –based study of breast cancer in Stockholm County. *Genet. Test.*, **8**, 127-32 (2004)

12 Mannisto, S. et al. Body-size indicators and risk of breast cancer according to menopause and estrogen-receptor status. *Int. J. Cancer,* **68**, 8-13 (1996).

Hartikainen, J.M. et al. An autosome-wide scan for linkage disequilibrium-based association in sporadic breast cancer cases in eastern Finland: three candidate regions found. *Cancer Epidemiol. Biomarkers Prev.,* **14**, 75-80 (2005).

13 Mann, G.J. et al. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. *Breast Cancer Res.,* **8**, R12 (2006).

Renwick, A. et al. Mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. *Nat. Genet.*,**38**, 873-5 (2006).

Beesley, J et al. Association between single nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: Results from two Australian studies and an additional validation set. *Cancer Epidemiol. Biomarkers Prev.,* **12**, 2257-65 (2007).

14 Kropp, S et al. Good agreement between physician and self-reported hormone therapy data in a case-control study *J. Clin. Epidemiol.*, **60**, 1280-7 (2007)

15 Olson, JE. et al. A comprehensive examination of CYP19 variation and breast density. *Cancer Epidemiol. Biomarkers Prev.* **16**, 623-5 (2007)

16 Giles GG. Et al. The Melbourne Collaborative Cohort Study. *IARC Sci. Publ.,* **156,** 69-70 (2002)

17 Kolonel, L. N. et al. A multi-ethnic cohort in Hawaii and Los Angeles; Baseline characteristics. *Am. J. Epidemiol.,* **151**, 346-357 (2000)

18 Nordgard SH. et al. Genome-wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients. *Genes Chromosomes Cancer*, **47**,680-96 (2008)

19 Hankinson SE. et al. Plasma sex steroid hormone levels and risk of breast cancer in post-menopausal women. *J. Natl. Cancer Inst.,* **96**,1866-9 (2004)

20 Huijts PE et al . Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases*. Breast Cancer Res.*, **9**, R78 (2007).

21 Garcia-Closas, M. et al. Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses. *Hum. Genet,* **119**, 376-88 (2006).

22, 23 Lesueur, F. et al. Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer. *Hum. Mol. Genet.,* **14**, 2349-56 (2005).

24 Lee, K.M. et al. Genetic polymorphisms of ataxia telangiectasia mutated and breast cancer risk. *Cancer Epidemiol. Biomarkers Prev.,* **14**, 821-5 (2005).

25 Wedren, S. et al. Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study. *Breast Cancer Res.,* **6**, R437-49 (2004).

Magnusson, C. et al. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. *Int J. Cancer,* **81**, 339-44 (1999).

26 Hsu, HM et al. Breast cancer risk is associated with genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex. *Cancer Epidemiol. Biomarkers Prev.* **16,** 2024-32 (2007)

27 Anton-Culver, H.et al. Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. *Eur. J. Cancer,* **36**, 1200-8 (2000)

Ziogas, A. et al. Cancer risk estimates for family members of a population-based family registry for breast and ovarian cancer. *Cancer Epidemiol. Biomarkers Prev.*, **9,** 103-11 (2000)

28 Sigurdson, A.J. et al. Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes. *B.M.C. Cancer*, **4**, 9 (2004).

Sigurdson, A.J. et al. Cancer incidence in the US radiologic technologists health study, 1983-1998. *Cancer,* **97**, 3080-9 (2003).